Amyris, Inc. (NASDAQ:AMRS) received a $15.00 price target from equities researchers at HC Wainwright in a research report issued to clients and investors on Friday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 457.62% from the stock’s previous close.
A number of other equities research analysts have also commented on AMRS. Zacks Investment Research raised Amyris from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 16th. ValuEngine downgraded Amyris from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Amyris presently has a consensus rating of “Hold” and an average target price of $31.13.
Amyris (NASDAQ AMRS) opened at 2.69 on Friday. The company has a 50 day moving average of $3.51 and a 200 day moving average of $5.88. Amyris has a 1-year low of $2.46 and a 1-year high of $18.15. The company’s market capitalization is $53.28 million.
Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by $0.30. The company had revenue of $25.68 million during the quarter, compared to analyst estimates of $23.68 million. The company’s revenue was up 167.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.06) earnings per share. On average, analysts predict that Amyris will post ($3.98) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/2801212/amyris-inc-amrs-pt-set-at-15-00-by-hc-wainwright.html.
In other Amyris news, Director Patrick Y. Yang acquired 300,000 shares of Amyris stock in a transaction on Friday, May 19th. The stock was purchased at an average price of $0.29 per share, for a total transaction of $87,000.00. Following the purchase, the director now directly owns 153,000 shares of the company’s stock, valued at $44,370. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 11.30% of the stock is owned by corporate insiders.
A hedge fund recently raised its stake in Amyris stock. Carl Domino Inc raised its position in shares of Amyris, Inc. (NASDAQ:AMRS) by 37.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 201,925 shares of the biotechnology company’s stock after buying an additional 54,925 shares during the period. Carl Domino Inc owned approximately 0.07% of Amyris worth $107,000 as of its most recent filing with the SEC.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.